Personensuche
Personensuche
Es wurde 1 Person gefunden.
FB Medizin, Universitätsklinikum Essen, Klinik für Hämatologie und Stammzelltransplantation
Anschrift
Hufelandstraße 55
45147 Essen
45147 Essen
Telefon
Telefax
E-Mail
Funktionen
-
, Klinik für Hämatologie
Aktuelle Veranstaltungen
-
2023 SS
Vergangene Veranstaltungen (max. 10)
-
2022 WS
-
2022 SS
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Baseline radiomics features and MYC rearrangement status predict progression in aggressive B-cell lymphomaIn: Blood Advances Jg. 7 (2023) Nr. 2, S. 214 - 223ISSN: 2473-9537; 2473-9529Online Volltext: dx.doi.org/ (Open Access)
-
Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomasIn: Cancer Cell Jg. 41 (2023) Nr. 1, S. 210 - 225.e5ISSN: 1535-6108; 1878-3686Online Volltext: dx.doi.org/
-
MRI-based long-term follow-up of indolent orbital lymphomas after curative radiotherapy : imaging remission criteria and volumetric regression kineticsIn: Scientific Reports Jg. 13 (2023) Nr. 1,ISSN: 2045-2322Online Volltext: dx.doi.org/ (Open Access)
-
Neutropenia-related aspergillosis in non-transplant haematological patients hospitalised under ambient air versus purified air conditionsIn: Mycoses (2023) in pressISSN: 1439-0507; 0933-7407; 0027-5557Online Volltext: dx.doi.org/ (Open Access)
-
A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma : Final results of the prospective, multicentre GOAL trialIn: British Journal of Haematology Jg. 198 (2022) Nr. 3, S. 482 - 491ISSN: 1365-2141; 0007-1048Online Volltext: dx.doi.org/ (Open Access)
-
A tumor volume and performance status model to predict outcome before treatment in diffuse large B-cell lymphomaIn: Blood Advances Jg. 6 (2022) Nr. 23, S. 5995 - 6004ISSN: 2473-9537; 2473-9529Online Volltext: dx.doi.org/ (Open Access)
-
AFM13 in patients with relapsed or refractory classical Hodgkin lymphoma : final results of an open-label, randomized, multicenter phase II trialIn: Leukemia and Lymphoma (2022)ISSN: 1042-8194; 1029-2403Online Volltext: dx.doi.org/
-
Cost-Effectiveness of Shortening Treatment Duration Based on Interim PET Outcome in Patients With Diffuse Large B-cell LymphomaIn: Clinical Lymphoma, Myeloma & Leukemia Jg. 22 (2022) Nr. 6, S. 382 - 392ISSN: 2152-2650; 2152-2669Online Volltext: dx.doi.org/ (Open Access)
-
Follicular lymphoma grade 3B and diffuse large B-cell lymphoma present a histopathological and molecular continuum lacking features of progression/ transformationIn: Haematologica / The Hematology Journal Jg. 107 (2022) Nr. 9, S. 2144 - 2153ISSN: 1592-8721; 0390-6078Online Volltext: dx.doi.org/ (Open Access)
-
Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma : First analysis of toxicity and efficacy signalsIn: Leukemia and Lymphoma Jg. 63 (2022) Nr. 1, S. 84 - 92ISSN: 1042-8194; 1029-2403Online Volltext: dx.doi.org/
-
Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphomaIn: Infection - A Journal of Infectious Disease Jg. 50 (2022) Nr. 4, S. 925 - 932ISSN: 1439-0973; 0300-8126Online Volltext: dx.doi.org/ (Open Access)
-
Interim FDG-PET analysis to identify patients with aggressive non-Hodgkin lymphoma who benefit from treatment intensification : A post-hoc analysis of the PETAL trialIn: Leukemia (2022) in pressISSN: 1476-5551; 0887-6924Online Volltext: dx.doi.org/ (Open Access)
-
Long-term follow-up and health-related quality of life among cancer survivors with stage IEA orbital-type lymphoma after external photon-beam radiotherapy : Results from a longitudinal studyIn: Hematological Oncology (2022) in pressISSN: 0278-0232; 1099-1069Online Volltext: dx.doi.org/ (Open Access)
-
Mitochondrial Kv1.3 Channels as Target for Treatment of Multiple MyelomaIn: Cancers Jg. 14 (2022) Nr. 8,ISSN: 2072-6694Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Outcomes of anti-programmed death 1 treatment for relapsed/refractory Hodgkin lymphoma : A German Hodgkin Study Group multicentre real-world analysisIn: British Journal of Haematology Jg. 198 (2022) Nr. 2, S. 401 - 404ISSN: 1365-2141; 0007-1048Online Volltext: dx.doi.org/ (Open Access)
-
Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma : International Metabolic Prognostic IndexIn: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 21, S. 2352 - 2360ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ (Open Access)
-
Reinduction therapy with everolimus in combination with dexamethasone, high-dose cytarabin and cisplatinum in patients with relapsed or refractory classical Hodgkin lymphoma : An experimental phase I/II multicentre trial of the German Hodgkin Study Group (GHSG HD-R3i)In: British Journal of Haematology Jg. 196 (2022) Nr. 3, S. 606 - 616ISSN: 1365-2141; 0007-1048Online Volltext: dx.doi.org/ (Open Access)
-
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma : Results of the Ro-CHOP Phase III Study (Conducted by LYSA)In: Journal of Clinical Oncology (JCO) Jg. 40 (2022) Nr. 3, S. 242 - 251ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
The ECHELON-2 Trial : 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphomaIn: Annals of Oncology Jg. 33 (2022) Nr. 3, S. 288 - 298ISSN: 1569-8041; 0923-7534Online Volltext: dx.doi.org/ (Open Access)
-
Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNAIn: Nature Biotechnology Jg. 39 (2021) Nr. 12, S. 1537 - 1547ISSN: 0733-222X; 1546-1696Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma : results from the prospective, multicenter PETAL and OPTIMAL>60 trialsIn: European Journal of Nuclear Medicine and Molecular Imaging (2021) in pressISSN: 1619-7089; 1619-7070Online Volltext: dx.doi.org/ (Open Access)
-
FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma : results from the prospective, multicenter PETAL and OPTIMAL>60 trialsIn: European Journal of Nuclear Medicine and Molecular Imaging (2021) in pressISSN: 0340-6997; 1619-7089Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Impact of germline polymorphisms in genes regulating glucose uptake on positron emission tomography findings and outcome in diffuse large B-cell lymphoma : results from the PETAL trialIn: Journal of Cancer Research and Clinical Oncology (2021) in pressISSN: 1432-1335; 0171-5216; 0084-5353; 0301-1585Online Volltext: dx.doi.org/ (Open Access)
-
Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations : Comparison of the Deauville 5-Point Scale and the ΔSUVmₐₓ MethodIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 62 (2021) Nr. 1, S. 37 - 42ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ (Open Access)
-
Interim PET in Diffuse Large B-Cell LymphomaIn: Journal of Nuclear Medicine (JNM) / Society of Nuclear Medicine and Molecular Imaging (SNMMI) (Hrsg.) Jg. 62 (2021) Nr. 8, S. 1068 - 1074ISSN: 1535-5667; 0161-5505; 2159-662X; 0022-3123; 0097-9058Online Volltext: dx.doi.org/ (Open Access)
-
Outcomes of Anti-PD1 Treatment for Relapsed/Refractory Hodgkin Lymphoma : A German Hodgkin Study Group (GHSG) Multi-Center Real-World AnalysisIn: Blood Jg. 138 (2021) Nr. Suppl. 1,ISSN: 1528-0020; 0006-4971Online Volltext: dx.doi.org/
-
PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17) : a multicentre, open-label, randomised, phase 3 trialIn: The Lancet Oncology Jg. 22 (2021) Nr. 2, S. 223 - 234ISSN: 1474-5488; 1470-2045Online Volltext: dx.doi.org/
-
Phase I/II trial of lenalidomide, methotrexate, leucovorin, cytarabine, and rituximab (LeMLAR) in relapsed or refractory diffuse large B cell lymphomaIn: Blood Cancer Journal Jg. 11 (2021) Nr. 5,ISSN: 2044-5385Online Volltext: dx.doi.org/ (Open Access)
-
Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomasIn: Blood Advances Jg. 5 (2021) Nr. 13, S. 2707 - 2716ISSN: 2473-9537; 2473-9529Online Volltext: dx.doi.org/ (Open Access)
-
Quantitative evaluation of interim positron emission tomography in peripheral T-cell lymphomaIn: EJNMMI Research Jg. 11 (2021) Nr. 1,ISSN: 2191-219XOnline Volltext: dx.doi.org/ (Open Access)
-
Short Diagnosis-to-Treatment Interval Is Associated With Higher Circulating Tumor DNA Levels in Diffuse Large B-Cell LymphomaIn: Journal of Clinical Oncology (JCO) Jg. 39 (2021) Nr. 23, S. 2605 - 2616ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Baseline and interim PET-based outcome prediction in peripheral T-cell lymphoma: A subgroup analysis of the PETAL trialIn: Hematological Oncology (2020)ISSN: 0278-0232; 1099-1069Online Volltext: dx.doi.org/ (Open Access)
-
Corrigendum to ‘Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial’ [Eur J Canc 124 (January 2020) 25–36] (European Journal of Cancer (2020) 124 (25–36), (S0959804919307555), (10.1016/j.ejca.2019.09.027))In: European Journal of Cancer (EJC) Jg. 136 (2020) S. 207 - 208ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/ (Open Access)
-
Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma : Post-hoc analysis from the PETAL trialIn: European Journal of Cancer Jg. 124 (2020) S. 25 - 36ISSN: 1879-0852; 0959-8049Online Volltext: dx.doi.org/
-
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma : The Randomized Phase 2 German Hodgkin Study Group NIVAHL TrialIn: JAMA Oncology Jg. 6 (2020) Nr. 6, S. 872 - 880ISSN: 2374-2445; 2374-2437Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Genetic Variants of the NKG2C/HLA-E Receptor : Ligand Axis Are Determinants of Progression-Free Survival and Therapy Outcome in Aggressive B-Cell LymphomaIn: Cancers Jg. 12 (2020) Nr. 11, S. 3429ISSN: 2072-6694Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Impact of complete surgical resection on outcome in aggressive non-Hodgkin lymphoma treated with immunochemotherapyIn: Cancer Medicine Jg. 99 (2020) Nr. 22, S. 8386 - 8396ISSN: 2045-7634Online Volltext: dx.doi.org/ (Open Access)
-
Metabolic tumor volume, cancer cell fraction, and prognosis–the case of T-cell/histiocyte-rich large B-cell lymphomaIn: Leukemia and Lymphoma Jg. 61 (2020) Nr. 6, S. 1372 - 1379ISSN: 1029-2403; 1042-8194Online Volltext: dx.doi.org/
-
Supporting data for positron emission tomography-based risk modelling using a fixed-instead of a relative thresholding method for total metabolic tumor volume determinationIn: Data in Brief Jg. 28 (2020)ISSN: 2352-3409Online Volltext: dx.doi.org/ (Open Access)
-
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2) : a global, double-blind, randomised, phase 3 trialIn: The Lancet Jg. 393 (2019) Nr. 10168, S. 229 - 240ISSN: 1474-547X; 0140-6736Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome PredictionIn: Cell Jg. 178 (2019) Nr. 3, S. 699 - 713.e19ISSN: 0092-8674; 1097-4172Online Volltext: dx.doi.org/ (Open Access)
-
Efficacy of the GMALL-B-ALL/NHL2002 protocol in Burkitt leukemia/lymphoma and aggressive non-Hodgkin-lymphomas with or without CNS involvementIn: European Journal of Haematology Jg. 102 (2019) Nr. 3, S. 241 - 250ISSN: 1600-0609; 0902-4441; 0036-553XOnline Volltext: dx.doi.org/
-
Molecular characteristics of diffuse large B-cell lymphoma in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin lymphomas (PETAL) trial : correlation with interim PET and outcomeIn: Blood Cancer Journal Jg. 9 (2019) Nr. 9, S. 67ISSN: 2044-5385Online Volltext: dx.doi.org/ (Open Access)
-
Reply to J. Wang et alIn: Journal of Clinical Oncology (JCO) Jg. 37 (2019) Nr. 9, S. 755 - 758ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Serologic response to meningococcal vaccination in patients with cold agglutinin disease (CAD) in the novel era of complement inhibitionIn: Vaccine Jg. 37 (2019) Nr. 44, S. 6682 - 6687ISSN: 1873-2518; 0264-410X; 1358-8745Online Volltext: dx.doi.org/
-
Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP : results from the “Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas” (PETAL) trialIn: Annals of Hematology Jg. 98 (2019) Nr. 4, S. 897 - 907ISSN: 1432-0584; 0939-5555; 0006-5242Online Volltext: dx.doi.org/
-
Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma : an analysis of the German Hodgkin Study Group (GHSG)In: Leukemia Jg. 33 (2019) Nr. 2, S. 439 - 446ISSN: 1476-5551; 0887-6924Online Volltext: dx.doi.org/
-
Treatment Outcome in Patients with Primary or Secondary Transformed Indolent B-Cell LymphomasIn: Oncology Research and Treatment Jg. 42 (2019) Nr. 11,ISSN: 2296-5262; 2296-5270Online Volltext: dx.doi.org/
-
Circulating tumor DNA measurements as early outcome predictors in diffuse large B-Cell lymphomaIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. 28, S. 2845 - 2853ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Eculizumab in cold agglutinin disease (DECADE) : an open-label, prospective, bicentric, nonrandomized phase 2 trial.In: Blood Advances Jg. 2 (2018) Nr. 19, S. 2543 - 2549ISSN: 2473-9537; 2473-9529Online Volltext: dx.doi.org/ (Open Access)
-
Genomic CDKN2A/2B deletions in adult Ph+ ALL are adverse despite allogeneic stem cell transplantationIn: Blood Jg. 131 (2018) Nr. 13, S. 1464 - 1475ISSN: 1528-0020; 0006-4971Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder : A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 TrialsIn: Transplantation Jg. 102 (2018) Nr. 11, S. 1914 - 1923ISSN: 1534-6080; 0041-1337Online Volltext: dx.doi.org/ (Open Access)
-
Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL) : A Multicenter, Randomized Phase III TrialIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. 20, S. 2024 - 2034ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Reply to H.J.A adams et al and C. GisselbrechtIn: Journal of Clinical Oncology (JCO) Jg. 36 (2018) Nr. 32, S. 3273 - 3274ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Complex Immune Evasion Strategies in Classical Hodgkin LymphomaIn: Cancer Immunology Research Jg. 5 (2017) Nr. 12, S. 1122 - 1132ISSN: 2326-6074; 2326-6066Online Volltext: dx.doi.org/
-
PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18) : final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study GroupIn: The Lancet Jg. 390 (2017) Nr. 10114, S. 2790 - 2802ISSN: 1474-547X; 0140-6736Online Volltext: dx.doi.org/
-
Randomized comparison of liposomal amphotericin B versus placebo to prevent invasive mycoses in acute lymphoblastic leukaemiaIn: Journal of Antimicrobial Chemotherapy Jg. 72 (2017) Nr. 8, S. 2359 - 2367ISSN: 0305-7453; 1460-2091Online Volltext: dx.doi.org/ (Open Access)
-
Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or r-chop consolidation in an international, prospective, multicenter Phase II trialIn: Journal of Clinical Oncology (JCO) Jg. 35 (2017) Nr. 5, S. 536 - 543ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Treatment reduction in patients with advanced-stage Hodgkin Lymphoma and negative interim PET : Final results of the international, randomized phase 3 trial HD 18 by the German Hodkin Study GroupIn: Haematologica Jg. 102 (2017) Nr. Suppl. 2, S. 24 - 25ISSN: 0390-6078; 1592-8721
-
Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML) : a multicentre, phase 2, randomised controlled trialIn: The lancet. Oncology Jg. 16 (2015) Nr. 16, S. 1691 - 1699ISSN: 1474-5488; 1470-2045Online Volltext: dx.doi.org/
-
Outcome of aggressive non-Hodgkin lymphoma patients with a negative pretreatment positron emission tomography scanIn: Leukemia and Lymphoma Jg. 56 (2015) Nr. 5, S. 1235 - 1235ISSN: 1042-8194; 1029-2403
-
Positron Emission Tomography guided therapy of aggressive lympomas (PETAL) - the predictive value of quantitative PETIn: Journal of Nuclear Medicine Jg. 56 (2015) Nr. Suppl. 3, S. 210ISSN: 0161-5505; 1535-5667
-
Updated results from the soraml trial comparing sorafenib versus placebo in addition to standard therapy in younger patients with newly diagnosted acute myeloid leukemiaIn: Haematologica Jg. 100 (2015) Nr. Suppl. 1, S. 318 - 318ISSN: 0390-6078; 1592-8721(Open Access)
-
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy : report of a large prospective multicenter trialIn: Blood Jg. 124 (2014) Nr. 26, S. 3870 - 3879ISSN: 1528-0020; 0006-4971Online Volltext: dx.doi.org/
-
Positron Emission Tomography (PET) Guided Therapy of Aggressive Lymphomas - a Randomized Controlled Trial Comparing Different Treatment Approaches Based on Interim PET Results (PETAL Trial)In: Blood Jg. 124 (2014) Nr. 21, S. 391ISSN: 1528-0020; 0006-4971Online Volltext: dx.doi.org/
-
Progranulin Is a Novel Independent Predictor of Disease Progression and Overall Survival in Chronic Lymphocytic LeukemiaIn: PLoS ONE Jg. 23 (2013) Nr. 8, S. e72107ISSN: 1932-6203Online Volltext: dx.doi.org/ (Open Access)
-
Epigenetic Silencing of the Circadian Clock Gene CRY1 is Associated with an Indolent Clinical Course in Chronic Lymphocytic LeukemiaIn: PLoS ONE Jg. 7 (2012) Nr. 12, S. e34347ISSN: 1932-6203Online Volltext: dx.doi.org/ (Open Access)
-
Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantationIn: Blood Jg. 120 (2012) Nr. 10, S. 2032 - 2041ISSN: 1528-0020; 0006-4971Online Volltext: dx.doi.org/
-
Prevalence and progression of monoclonal gammopathy of undetermined significance and light-chain MGUS in GermanyIn: Annals of Hematology Jg. 91 (2012) Nr. 2, S. 243 - 248ISSN: 1432-0584; 0939-5555; 0006-5242Online Volltext: dx.doi.org/
-
Progranulin plasma concentration is a novel independent prognostic marker in chronic lymphocytic leukemiaIn: Onkologie Jg. 35 (2012) Nr. Suppl. 6, S. 100ISSN: 0378-584X; 1423-0240
-
The GMALL-B-ALL/NHL protocol is an effective salvage treatment in relapsed and refractory aggressive B-cell non-Hodgkins lymphomasIn: Onkologie Jg. 35 (2012) Nr. 6, S. 40ISSN: 0378-584X; 1423-0240
-
High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantationIn: Blood Jg. 118 (2011) Nr. 13, S. 3504 - 3511ISSN: 1528-0020; 0006-4971Online Volltext: dx.doi.org/
-
Inhibition of the Terminal Complement System Using Eculizumab for the Treatment of Cold Agglutinin Disease (CAD)
184. Tagung der Rheinisch-Westfälischen Gesellschaft für Innere Medizin e.V.,In: Medizinische Klinik Jg. 105 (2010) Nr. 3, S. 213 - 214ISSN: 0723-5003; 1615-6722Online Volltext: dx.doi.org/ -
Pitfalls of interim positron emission tomography scanning in diffuse large B-cell lymphomaIn: Journal of Clinical Oncology (JCO) Jg. 28 (2010) Nr. 27, S. e488 - e489ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
Porphyria cutanea tardaIn: British Journal of Haematology Jg. 148 (2010) Nr. 4, S. 493ISSN: 1365-2141; 0007-1048Online Volltext: dx.doi.org/
-
Prevalence of monoclonal gammopathy of undetermindes significance in a densley populated, highly industrialized area in Germany
15th Congress of the European Hematology Association, Spain, Barcelona, June 10–13, 2010,In: Haematologica, the hematology journal Jg. 95 (2010) Nr. Suppl. 2, S. 394, 0949ISSN: 0390-6078; 1592-8721 -
Prevalence of monoclonal gammopathy of undetermined significance in a densely populated, highly industrialized area in Germany
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010,In: Onkologie Jg. 33 (2010) Nr. Suppl. 6, S. 95, V321ISSN: 0378-584X; 1423-0240Online Volltext: dx.doi.org/ -
Prognostic Significance of Molecular Remission in Follicular LymphomaIn: Journal of Clinical Oncology Jg. 28 (2010) Nr. 30, S. e613ISSN: 1527-7755; 0732-183XOnline Volltext: dx.doi.org/
-
Gene expression signatures separate B-cell chronic lymphocytic leukaemia prognostic subgroups defined by ZAP-70 and CD38 expression statusIn: Leukemia Jg. 20 (2006) Nr. 10, S. 1774 - 1782ISSN: 0887-6924; 1476-5551Online Volltext: dx.doi.org/
-
Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemiaIn: Leukemia & Lymphoma Jg. 47 (2006) Nr. 6, S. 1053 - 1061ISSN: 1029-2403Online Volltext: dx.doi.org/
-
Expression of ribosomal and translation-associated genes is correlated with a favorable clinical course in chronic lymphocytic leukemiaIn: Blood Jg. 101 (2003) Nr. 7, S. 2748 - 2755ISSN: 1528-0020; 0006-4971Online Volltext: dx.doi.org/
-
CD38 expression is an important prognostic marker in chronic lymphocytic leukaemiaIn: Leukemia Jg. 16 (2002) Nr. 1, S. 30 - 35ISSN: 0887-6924; 1476-5551Online Volltext: dx.doi.org/
-
PET/CT bei indolenten Lymphoma : wann und warum?
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 7.–10. Oktober 2022, Wien, Austria,In: Oncology Research and Treatment Jg. 45 (2022) Nr. Supplement 2, S. 147ISSN: 2296-5262; 2296-5270; 1423-0240; 0378-584XOnline Volltext: dx.doi.org/ (Open Access) -
Echelon-2 (NCT01777152), a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin plus CHP VS CHOP in Previously Untreated Patients with CD30-Positive Peripheral T-Cell Lymphoma : 5-Year Results
48th Congress of the Italian Society of Hematology, 24-27 October 2021, Milan, Italy,In: Haematologica / The Hematology Journal Jg. 106 (2021) Nr. 10, S3: 48th Congress of the Italian Society of Hematology, 24-27 October 2021, S. 3ISSN: 1592-8721; 0390-6078Online Volltext: dx.doi.org/ (Open Access) -
Phased variants improve DLBCL minimal residual disease detection at the end of therapyIn: Journal of Clinical Oncology Jg. 39 (2021) Nr. 15_Suppl, S. 7565 - 7565ISSN: 0732-183X; 1527-7755Online Volltext: dx.doi.org/
-
The ECHELON-2 Trial : 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-Positive Peripheral T-Cell Lymphoma
Society of Hematologic Oncology 9th Annual Meeting ; September 8–11, 2021, Houston, Texas, USA & Virtual Venue,In: Clinical Lymphoma, Myeloma & Leukemia Jg. 21 (2021) Nr. Suppl. 1, S. S411ISSN: 2152-2650; 2152-2669Online Volltext: dx.doi.org/ -
AFM13 in patients with relapsed or refractory Hodgkin Lymphoma : Final results of an open-label, randomized, multicenter phase II trial
Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,In: Oncology Research and Treatment Jg. 43 (2020) Nr. Suppl. 4, S. 89ISSN: 2296-5270; 2296-5262; 1423-0240; 0378-584XOnline Volltext: dx.doi.org/ (Open Access) -
Characteristics of the relationship between MTV and survival in diffuse large B-cell lymphoma : A PETRA consortium study
EANM‘20 ; Annual Congress of the European Association of Nuclear Medicine ; October 22 – 30, 2020, Wien, Virtual,In: European Journal of Nuclear Medicine and Molecular Imaging Jg. 47 (2020) Nr. Supplement 1, S. S357ISSN: 1619-7070; 1619-7089Online Volltext: dx.doi.org/ (Open Access) -
Classical Hodgkin-Lymphoma : PET-guided therapy and implementation of new substances from a global perspective
Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,In: Oncology Research and Treatment Jg. 43 (2020) Nr. Suppl. 4, S. 4ISSN: 2296-5270; 2296-5262; 1423-0240; 0378-584XOnline Volltext: dx.doi.org/ (Open Access) -
FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma : results from the prospective, multicenter PETAL and OPTIMAL > 60 trials
Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,In: Oncology Research and Treatment Jg. 43 (2020) Nr. Suppl. 4, S. 55 - 56ISSN: 2296-5270; 2296-5262Online Volltext: dx.doi.org/ (Open Access) -
Think twice : Anemia of chronic disease (ACD) due to angiomatoid fibrous histiocytoma (AFH)
Virtuelle Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 09.–11. Oktober 2020,In: Oncology Research and Treatment Jg. 43 (2020) Nr. Suppl. 4, S. 181ISSN: 2296-5270; 2296-5262; 1423-0240; 0378-584XOnline Volltext: dx.doi.org/ (Open Access) -
Interim results of a multicenter, single-arm study to assess Blinatumomab in adult patients (pts) with minimal residual disease (MRD) of B-precursor (BCP) acute lymphoblastic leukemia (GMALL-MOLACT1-BLINA)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 11. - 14. Oktober 2019, Berlin,In: Oncology Research and Treatment Jg. 42 (2019) Nr. Suppl 4, S. 174 - 175ISSN: 2296-5270; 0378-584X; 1423-0240; 2296-5262Online Volltext: dx.doi.org/ (Open Access) -
Nivolumab and AVD for Early-Stage Unfavorable Hodgkin Lymphoma (NIVAHL)
61st ASH (American Society of Hematology) Annual Meeting & Exposition; Dec 07 - 10 2019; Oralndo, USA,In: Blood Jg. 134 (2019) Nr. Supplement_1, S. 236 - 236ISSN: 0006-4971; 1528-0020Online Volltext: dx.doi.org/ (Open Access) -
Role of FDG PET/CT to Detect Bone Marrow Involvement in the Initial Staging of Aggressive Non-Hodgkin Lymphoma
Konferenz 61st ASH (American Society of Hematology) Annual Meeting & Exposition; Dec 07 - 10 2019; Oralndo, USA,In: Blood Jg. 134 (2019) Nr. Supplement_1, S. 2892 - 2892ISSN: 1528-0020; 0006-4971Online Volltext: dx.doi.org/ (Open Access) -
Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma
61st ASH Annual Meeting and Exposition, 07.-10.12.2019, Orlando, FL,In: Blood Jg. 134 (2019) Nr. Supplement_1, S. 491 - 491ISSN: 1528-0020; 0006-4971Online Volltext: dx.doi.org/ (Open Access) -
The ECHELON-2 trial : Results of a randomised, double-blind, active-controlled phase 3 study of brentuximab vedotin and CHP (A+CHP) vs CHOP in the frontline treatment of patients (pts) with CD30⁺ peripheral T-cell lymphomas (PTCLs)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 11. - 14. Oktober 2019, Berlin,In: Oncology Research and Treatment Jg. 42 (2019) Nr. Suppl 4, S. 23ISSN: 2296-5270; 0378-584X; 1423-0240; 2296-5262Online Volltext: dx.doi.org/ (Open Access) -
The Optimal Timing of Interim 18F-FDG PET in Diffuse Large B-Cell Lymphoma : An Individual Patient Data Meta-Analysis By the Petra Consortium
61st ASH Annual Meeting and Exposition, 07.-10.12.2019, Orlando, FL,In: Blood Jg. 134 (2019) Nr. Supplement_1, S. 487ISSN: 1528-0020; 0006-4971Online Volltext: dx.doi.org/ -
Induction Therapy with Everolimus in Combination with DHAP (Dexamethasone, High-Dose AraC, Cisplatinum) in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma : A Randomized, Placebo-Controlled Phase I/II Trial (HD-R3i)
60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood Jg. 132 (2018) Nr. Supplement 1, S. 2912 - 2912ISSN: 1528-0020; 0006-4971Online Volltext: dx.doi.org/ (Open Access) -
Interim PET-Based Outcome Prediction in Diffuse Large B-Cell Lymphoma Patients Participating in the Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL) Trial : Comparison of the Delta SUV Max Method and the Deauville 5-Point Scale
60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood Jg. 132 (2018) Nr. Supplement 1, S. 1696 - 1696ISSN: 1528-0020; 0006-4971Online Volltext: dx.doi.org/ -
Lymphoma Virome Dynamics Revealed By Cell-Free DNA Sequencing
Konferenz 60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood Jg. 132 (2018) Nr. Supplement 1, S. 2861 - 2861ISSN: 1528-0020; 0006-4971Online Volltext: dx.doi.org/ (Open Access) -
Molecular Characteristics of Diffuse Large B-Cell Lymphoma and Correlation with Baseline Metabolic Tumor Volume (MTV), Interim Positron Emission Tomography (iPET) and Outcome in the PETAL Trial
60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood Jg. 132 (2018) Nr. Supplement 1, S. 4188 - 4188ISSN: 0006-4971; 1528-0020Online Volltext: dx.doi.org/ (Open Access) -
Noninvasive Genotyping and Monitoring of Classical Hodgkin Lymphoma
60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood Jg. 132 (2018) Nr. Supplement 1, S. 2838 - 2838ISSN: 1528-0020; 0006-4971Online Volltext: dx.doi.org/ (Open Access) -
Obinutuzumab (GA101) in Combination with Pixantrone for the Treatment of Patients with Relapsed Aggressive B-Cell Lymphoma : Â a Phase II Trial (GOAL)
60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood Jg. 132 (2018) Nr. Supplement 1, S. 1678 - 1678ISSN: 1528-0020; 0006-4971Online Volltext: dx.doi.org/ (Open Access) -
Predominantly motor polyneuropathy following brentuximab vedotin
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 4, S. 319ISSN: 2296-5262; 2296-5270Online Volltext: dx.doi.org/ (Open Access) -
The ECHELON-2 Trial : Results of a Randomized, Double-Blind, Active-Controlled Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients with CD30+ Peripheral T-Cell Lymphomas
60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood Jg. 132 (2018) Nr. Supplement 1, S. 997 - 997ISSN: 0006-4971; 1528-0020Online Volltext: dx.doi.org/ (Open Access) -
The addition of sorafenib to standard AML treatment results in a substantial reduction in relapse risk and improved survival : Updated results from long-term follow-up of the randomized-controlled SORAML trial
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 28. September - 2. Oktober 2018, Wien,In: Oncology Research and Treatment Jg. 41 (2018) Nr. Suppl. 4, S. 9ISSN: 2296-5262; 2296-5270Online Volltext: dx.doi.org/ (Open Access) -
Positron-emission tomography-guided therapy of aggressive non-Hodgkin lymphomas -final results of the PETAL trialIn: Oncology Research and Treatment Jg. 40 (2017) Nr. Suppl. 3, S. 202 - 203ISSN: 2296-5270; 0378-584X; 2296-5262; 1423-0240Online Volltext: dx.doi.org/
-
DECADE Trial : Inhibition of theterminal complement system using the anti-C5 antibody eculizumab for the treatment of cold agglutinin disease (CAD)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010,In: Onkologie Jg. 33 (2010) Nr. Suppl. 6, S. 112ISSN: 0378-584X; 1423-0240Online Volltext: dx.doi.org/ -
Prevalence of Monoclonal Gammopathy of Undetermined Significance (MGUS) and Light-Chain MGUS (LCMGUS) In a Metropolitan Area In GermanyIn: Blood Jg. 116 (2010) Nr. 21,ISSN: 1528-0020; 0006-4971Online Volltext: dx.doi.org/